Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage biopharmaceutical company developing oncology therapies that exploit specific vulnerabilities in cancer cell mutations while aiming to spare healthy tissue. News about Aprea focuses on the progress of its precision oncology pipeline, centered on DNA damage response–related targets.
The company’s updates frequently cover clinical data from its lead programs. APR-1051, an oral WEE1 kinase inhibitor, is being studied in the biomarker-focused Phase 1 ACESOT-1051 trial in advanced solid tumors. Press releases describe early signals of anti-tumor activity and disease stabilization in heavily pretreated gastrointestinal, gynecologic, and HPV-positive head and neck cancers, as well as details on dose escalation, safety, and biomarker-defined patient cohorts.
News flow also highlights ATRN-119, Aprea’s macrocyclic ATR inhibitor in the Phase 1/2a ABOYA-119 trial. The company reports identification of a recommended Phase 2 dose for once-daily dosing, early evidence of disease stabilization, and examples of tumor shrinkage in patients with DDR-related gene mutations. Recent announcements describe a strategic shift toward evaluating ATRN-119 in combination with radiation, immune checkpoint inhibitors, and antibody-drug conjugates, and the pausing of further monotherapy enrollment.
Investors following APRE news will also see regular financial results releases, updates on cash runway, private placement financings, and participation in scientific and investor conferences such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the H.C. Wainwright Global Investment Conference. Together, these items provide an ongoing view of Aprea’s clinical development milestones, research collaborations, and corporate activities.
Aprea Therapeutics, Inc. (Nasdaq: APRE) has completed patient enrollment in its Phase 3 trial for eprenetapopt, a treatment targeting front-line TP53 mutant myelodysplastic syndromes (MDS). Topline results are anticipated by year-end 2020. The trial, involving 154 patients, compares eprenetapopt with azacitidine against azacitidine alone, focusing on the complete response rate. Aprea plans to submit applications for regulatory approvals in the U.S. and EU in 2021, bringing hope for a much-needed therapy for patients suffering from TP53 mutated MDS.
Aprea Therapeutics (APRE) reported its Q1 2020 financial results on May 15, 2020, showcasing a net loss of $9.4 million, or $0.45 per share, compared to a loss of $3.5 million, or $2.97 per share in Q1 2019. The company's cash and cash equivalents totaled $122.5 million, sufficient to support operations through 2023. Despite challenges from COVID-19, patient enrollment in clinical trials for its lead compound, eprenetapopt, is improving. Aprea has received FDA Breakthrough Therapy Designation for eprenetapopt in combination with azacitidine for MDS treatment.